Table 1.
Study population for B-cell functional studies.
| Healthy controls | AAV remission | p-value | |
|---|---|---|---|
| Number of individuals: n (female/male) | 8 (3/5) | 7 (2/5) | 1.00 |
| Age: median years (range) | 69 (68–71) | 69 (38–84) | 0.845 |
| ANCA at diagnosis: PR3/MPO | na | 7/0 | – |
| GPA/MPA | na | 7/0 | – |
| Lymphocytes: median x109/L (IQR) | 1.8 (1.6–2.7) | 1.4 (1.2–1.9) | 0.186 |
| Creatinine: median μmol/L (range) | 83 (52–113) | 91 (82–123) | 0.244 |
| C-reactive protein: median mg/L (range) | <5 | <5 (<5–7) | – |
| TREATMENT AT TIME OF SAMPLING: | |||
| Prednisolone, n (%) | na | 5 (71) | – |
| Prednisolone, median mg/day (range) | na | 2.5 (0–3.8) | – |
| Azathioprine, n (%) | na | 1 (14) | – |
| Methotrexate, n (%) | na | 3 (43) | – |
| No immunosuppressive therapy, n (%) | na | 0 (0) | – |
| PRIOR TREATMENT: | |||
| Rituximab: n (%) | na | 2 (29) | – |
| Time since rituximab at sampling in treated patients: median months (range) | na | 66 (43–90) | – |
AAV, ANCA-associated vasculitis; PR3, proteinase 3; MPO, myeloperoxidase; GPA, granulomatous with polyangiitis; MPA, microscopic polyangiitis; na, not applicable.
Fisher's exact test was used to compare discrete variables and Mann-Whitney U test for continuous variables bwteen the groups.
Significance assumed at p < 0.05.